GeoVax Labs (NASDAQ:GOVX) Posts Earnings Results

GeoVax Labs (NASDAQ:GOVX) issued its earnings results on Wednesday. The company reported $1.85 earnings per share (EPS) for the quarter, FiscalAI reports.

GeoVax Labs Price Performance

GeoVax Labs stock traded down $0.04 during mid-day trading on Wednesday, hitting $1.30. The company’s stock had a trading volume of 61,865 shares, compared to its average volume of 130,200. The firm’s 50 day moving average is $1.68 and its 200 day moving average is $6.57. The company has a market cap of $2.37 million, a PE ratio of -0.04 and a beta of 3.81. GeoVax Labs has a 52-week low of $1.14 and a 52-week high of $34.75.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on GOVX shares. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. Wall Street Zen cut GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Finally, D. Boral Capital reissued a “hold” rating on shares of GeoVax Labs in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs presently has a consensus rating of “Hold” and a consensus target price of $175.00.

Hedge Funds Weigh In On GeoVax Labs

A number of large investors have recently made changes to their positions in GOVX. Sabby Management LLC acquired a new stake in shares of GeoVax Labs during the third quarter worth approximately $313,000. Renaissance Technologies LLC acquired a new position in GeoVax Labs in the 4th quarter valued at approximately $104,000. Jane Street Group LLC purchased a new stake in GeoVax Labs in the 4th quarter worth approximately $99,000. Armistice Capital LLC acquired a new stake in shares of GeoVax Labs during the 3rd quarter valued at $253,000. Finally, HRT Financial LP purchased a new position in shares of GeoVax Labs during the 4th quarter valued at $31,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.